“超声信息管理系统”中的数据整合

介绍“超声信息管理系统”中的数据整合研究。医院数学化仪器和计算机信息系统的使用积累了大量的数据,本文针对“高血压进程与心脏形态变化的关系”这一主题,重组计算机内的积累病例数据,在建立数据仓库和实现数据挖掘方面做了一些尝试。     

针刺治疗视网膜色素变性的组穴规律分析

目的:基于数据挖掘技术分析文献中针刺治疗视网膜色素变性穴位的组方规律。方法:检索国家知识基础设施数据库（CNKI）、中国学术期刊数据库（CSPD）、中文科技期刊数据库（CCD）文献中治疗视网膜色素变性所使用的穴位处方,使用中医传承计算平台（V3.1）进行数据挖掘,分析针刺治疗视网膜色素变性的取经、选穴和配伍规律。结果:共纳入文献47篇,应用频次前5位的腧穴为球后、睛明、太阳、足三里、合谷;奇穴选用频次最高,经脉选用频次前3位依次为足太阳膀胱经、足少阳胆经、足阳明胃经;取穴部位以头颈部选取最多;其次为下肢部和上肢部。结论:针刺治疗视网膜色素变性的核心经脉为足太阳膀胱经、足少阳胆经及足阳明胃经,核心组穴为球后、睛明及太阳,配以足三里、合谷、光明、三阴交等穴,其取穴规律以局部取穴以及邻近取穴直达病所为主,远端取穴以足三里、合谷等辅以调理脏腑经络。     

基于数据挖掘的中医药治疗小儿湿疹组方用药规律研究

目的：通过应用中医传承辅助平台（V 2.5）挖掘中医药治疗小儿湿疹的组方用药规律,并对高频药物、用药模式及治疗思路进行探讨。方法：搜集国家知识基础设施数据库（CNKI）、中国学术期刊数据库（CSPD）及中文科技期刊数据库（CCD）中2000—2021年应用中医药治疗小儿湿疹的相关文献,经过筛选后建立方药数据库,运用中医传承辅助平台（V 2.5）集成的改进互信息法、关联规则Apriori算法、复杂系统熵聚类与无监督熵聚类等算法对药物频次、性味归经、用药模式、规则分析及新处方等结果进行输出,并进行网络可视化展示。结果：纳入处方200首,共涉及206味中药,高频药物包括甘草、白鲜皮、薏苡仁、茯苓、生地黄、金银花、蝉蜕、地肤子、防风、牡丹皮等,药性以寒性（52.76%）居多,药味以甘（38.89%）、苦（33.37%）、辛（21.96%）味为主,归经以胃经（1 138次）、脾经（1 088次）、肝经（1 061次）居多,并且得到药物之间的关联规则,以及新处方6个。结论：小儿湿疹用药以补虚药、利水渗湿药、清热药、清热解毒药、解表药为主,治疗以疏风清热,燥湿健脾,养血活血为主要大法,分析结果与本病诊疗指南较为吻合,可为小儿湿疹的临床治疗及新药开发提供参考。     

数据挖掘在名老中医经验传承的应用现状与智能化趋势

现在,数据挖掘技术正朝着智能化的趋势快速发展,人工智能（AI）在西医学的广泛应用,尤其是AI分析方法在疾病早期诊断与评估、疾病的治疗策略与医疗资源管理这几个方面突出的使用效果,为AI与中医药的结合提供了有价值的参考,尤其在名老中医经验的学习与传承方面。近十余年来,名老中医经验学习与传承领域数据挖掘技术的研究成果颇多,在梳理常用数据挖掘工具与分析方法的基础上,结合AI分析方法在西医学的应用,可以对中医药领域数据挖掘的智能化学习发展方向进行预测与展望,为继承与发展名老中医经验提供更高效的途径,加快中医现代化研究。     

Estimating pneumococcal vaccine coverage among Australian Indigenous children and children with medically at-risk conditions using record linkage

BackgroundRisk-based recommendations are common for pneumococcal vaccines but little is known about their uptake. In Australia, pneumococcal conjugate vaccine (PCV) was funded only for Aboriginal or Torres Strait Islander (Indigenous) children and those with underlying medical conditions in 2001, and then there were different booster dose recommendations depending on risk after the introduction of universal PCV vaccination in 2005.MethodsWe measured coverage of PCV dose 3 and additional PCV and 23-valent pneumococcal polysaccharide vaccine (PPV23) doses by risk group among children born in July 2001–December 2012 in two Australian states using linked immunisation and hospitalisation data (available until December 2013). We ascertained medical risk conditions using hospitalisation diagnosis codes and Indigenous status using an established algorithm, comparing coverage for children born pre (2001–2004) and post (2005–2012) universal PCV funding.ResultsAmong 1.3 million children, 63,897 (4.9%) were Indigenous and 32,934 (2.5%) had at least one medically at-risk condition identified by age 6 months. For births in 2001–2004, coverage for PCV dose 3 by 1 year of age was 37% for Indigenous, 15% for medically at-risk and 11% in other children, increasing to 83%, 91% and 92%, respectively for births in 2005–2012. In children with medically at-risk conditions, PCV dose 4 coverage by 2 years was 1% for 2001–2004 births, increasing to 9% for 2005–2012 births, with PPV23 coverage by 6 years 3% in both cohorts. Among eligible Indigenous children, PPV23 coverage by 3 years was 45% for 2001–2004 births and 51% for 2005–2012 births.ConclusionsCoverage with additional recommended booster doses was very low among children with medical conditions, and only modest among Indigenous children. If additional PCV doses are recommended for some risk groups, especially in the context of routine schedules with reduced doses (e.g. 2 + 1 and 1 + 1), measures to improve implementation will be required.     

基于统计参数图的脑功能磁共振成像数据处理方法

介绍了基于统计参数图的脑功能磁共振成像数据处理方法。脑功能磁共振成像由于其高的时间、空间分辨率、无创性等特点而得到广泛的应用。使用统计参数图进行脑功能成像的数据处理过程主要分为:原始数据的读取、图像预处理、统计分析和统计推论。图像预处理包括运动伪影的消除、图像标准化、图像空间平滑;统计分析包括广义线性模型的建立;统计推论包括T检验等。重点介绍了各个过程所使用的传统的处理方法和最新的处理方法。     

The impact of the internal market on hospital efficiency, productivity and service quality

In this paper we use nonparametric mathematical programming models to compute and decompose Malmquist indices of productivity and quality change, which are used to evaluate the reforms in the UK National Health Service in the early nineties. We focus on acute hospitals and we study them over the first five years of the reforms. The findings of the study indicate that there was a productivity slowdown in the first year after the reforms but productivity progress in the subsequent years and thus, overall there was a net gain in productivity over the entire period considered. Productivity trends were dominated by technical change rather than hospital relative efficiency changes, as hospitals were already largely relatively efficient at the time of the introduction of the reforms. In fact, over the last four years in the period studied there was small relative efficiency regress and this does not bear out the argument that the reforms would increase hospital efficiency. The productivity changes are similar when service quality is incorporated in the analysis but the magnitude of these changes diminishes. Quality of service followed different trends to productivity change and this may have been the price for the productivity gains achieved.     

Modell eines computergestützten qualitätssicherungssystems in der verbrennungsintensivtherapie

Zusammenfassung Ausgehend von Überlegungen für ein angemessenes Qualitätssicherungssystem im intensiv-medizinischen Bereich werden die Voraussetzungen für ein ganzheitliches Qualitätsmanagementsystem im Krankenhaus entworfen. Die Grundlage für ein dynamisches Qualitätssicherungssystem ist auf der dokumentatorischen Ebene eine umfassende Datenbasis, die auf einer zeitlich und datentechnisch unbegrenzten Patientenakte basiert. Die notwendige Hard- und Softwarestruktur wird durch die konsequente Anwendung einer Client-Server-Architektur gewährleistet. Die ständige Überprüfung der bestehenden Qualitätsziele in einem ökonomischen Regelkreis benötigt ein System mit flexiblen Abfragemechanismen. Dieser informatorische Datenzugriff auf jeder Hierarchieebene der Krankenhausstruktur wird durch das Konzept des Data-Warehouse ermöglicht, das als Datenbanksystem mit subjektorientierten, integrierten, zeitvariablen und beständigen Informationen konzipiert ist.

---

A computer-assisted quality-assurance model for burn intensive care applications

The prerequisites for an integrated quality management system for hospitals were developed as a result of considerations regarding the necessity of an appropriate quality-assurance system for the intensive care sector. The basis for a dynamic quality-assurance system on the documentational level is a comprehensive data base containing patient files unlimited in terms of time and data technology. The necessary hardware and software structure will be provided by consistent application of a client-server architecture. Permanent surveillance of existing quality objectives within the scope of an economic close-loop system requires a system with flexible query mechanisms. Informational data access from all hierarchical level within the hospital organization is facilitated by the data warehouse concept, a data base system with subject-oriented, integrated, time-variable, and persistent data.

     

Drug discovery information integration: virtual humans for pharmacokinetics

The ‘virtual human’ refers to simulation models based on explicit mathematical models of mammalian physiology. When applied to pharmacokinetics (PK), the virtual human embodies models that can be parameterised for different species, different individuals and populations of individuals, and that allow simulation of PK from measured and/or predicted in vitro properties. The models are independent of the properties of any specific drug, and can be used for the prediction of drug behaviour in specific human individuals and in pre-clinical species. The hope is that these models will allow the prediction of PK throughout the drug discovery and development process, enabling effective targeting of synthetic chemistry efforts to compounds with the required therapeutic effect, careful evaluation of multiple candidates for development, assessment of the potential for drug-drug interactions, evaluation of multiple formulations, efficient clinical trial design and other benefits, including reduction of animal usage in drug discovery. However, we believe that the biggest impact on drug discovery productivity would accrue from achieving two clear objectives: an estimate of human in vivo activity on every compound synthesised and a reliable prioritisation, based on predictions of human in vivo activity, for the next round of synthesis. It is realistic to believe that the benefits of delivering these objectives could, through shortening the time to decision and increasing the chance of success, lead to a five- to ten-fold increase in discovery output. It is also now possible to demonstrate that a combination of virtual human simulation software and industrial-scale absorption, distribution, metabolism and elimination (ADME) testing can deliver both of these objectives.